Skip to content

News & Events

Academic GI Cancer Consortium (AGICC)

Explore AGICC

AGICC Home
Institutions & Investigators
About
Facts
Publications

Explore Oncology Consortia

Myeloma (AMyC)
Breast Cancer (ABRCC)
Thoracic Oncology (ATOMIC)
GU Cancer (AURIC)
Academic GI Cancer Consortium Multicenter Phase II Trial Published in The Oncologist
A collaborative study from the Academic GI Cancer Consortium (AGICC) has been published in The Oncologist, reporting results from a multicenter Phase II trial evaluating FOLFOXIRI plus panitumumab as first-line therapy for patients with left-sided, RAS wild-type metastatic colorectal cancer. The study demonstrated a 74% objective response rate, 96% disease control rate, and median progression-free survival of 17 months, with the authors reporting response and progression-free survival outcomes among the highest reported in stage IV colon cancer.
ASCO Gastrointestinal Cancers Symposium – January 8-10, 2026
We are excited to attend the 2026 ASCO Gastrointestinal Cancers Symposium, held in San Francisco on January 8-10, 2026. Our semi-annual Investigator's Meeting of the Academic GI Cancer Consortium (AGICC)​ will be held on Thursday, January 8th, bringing together AGICC researchers to discuss new developments, collaboration opportunities and potential studies for 2026. 
A University of Colorado Leader Gets a Voice on National Cancer Research Policy
Congratulations to Wells Messersmith, MD, Director of Criterium's Academic GI Cancer Consortium (AGICC) on his appointment to the National Cancer Institute’s Board of Scientific Advisors. 
Criterium’s Oncology Consortia Makes Waves at ASCO 2024 Annual Conference
Dr. Deirdre Cohen and Dr. Robert Lentz, principal investigators with the Academic GI Cancer Consortium, attended the ASCO 2024 Annual Conference and shared valuable insights and progress from their innovative research model and clinical trials.
AGICC Investigator’s Meeting – Investigators Meet at ASCO GI For the First Time Since Covid
AGICC (Academic GI Cancer Consortium) met in person for an Investigator’s Meeting during the recent GI-ASCO 2023 Symposium in San Francisco. This coming year the AGICC group will continue to explore GI oncology trials in partnership with pharmaceutical companies. 
« Prev12Next »